万泰生物：公司20价肺炎结合疫苗I期临床已完成

Group 1 - The core viewpoint of the article is that Wantai Biological has completed Phase I clinical trials for its 20-valent pneumonia conjugate vaccine and will plan further development according to its overall strategy [2] Group 2 - The company has engaged with investors through an interactive platform to provide updates on its vaccine development [2] - The development plan for the pneumonia vaccine will align with the company's broader strategic objectives [2]